THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 11, Issue 5, 2011, Pages 627-637

  Sastre Garriga, Jaume ^a   Vila, Carlos ^b   Clissold, Stephen ^c   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Almirall SA ^*  (Spain)

^c Content Ed Net ^*  (Spain)

Author keywords

cannabidiol; delta 9 tetrahydrocannabinol; multiple sclerosis; nabiximols; Sativex; spasticity

Indexed keywords

CANNABIDIOL; CANNABIS; PLACEBO; TETRAHYDROCANNABINOL;

ABDOMINAL PAIN; AEROSOL; ALERTNESS; AMNESIA; ANOREXIA; APPLICATION SITE DISCOMFORT; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BALANCE DISORDER; CLINICAL RESEARCH; CONSTIPATION; DAILY LIFE ACTIVITY; DELUSIONAL DISORDER; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DISORIENTATION; DISSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUNK SENSATION; DYSARTHRIA; DYSGEUSIA; EUPHORIA; FATIGUE; GLOSSODYNIA; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; ILLUSION; INCIDENCE; INFECTION; INFESTATION; LETHARGY; MALAISE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MOUTH PAIN; MOUTH ULCER; MULTIPLE SCLEROSIS; NAUSEA; PARANOIA; PHARYNGITIS; SIDE EFFECT; SOMNOLENCE; SPASTICITY; SUICIDAL IDEATION; SYNCOPE; TACHYCARDIA; THROAT IRRITATION; VERTIGO; WELLBEING;

ADMINISTRATION, MUCOSAL; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PARASYMPATHOLYTICS; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79955663620     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.47     Document Type: Article

References (45)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 343, 938-952 (2000).
2. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transaction in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998). (Pubitemid 28065253)
3. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: Implications for resource allocation and health economic models. Health Technol. Assess. 6, 1-73 (2002).
4. Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur. J. Neurol. 12(Suppl. 1), 63-67 (2005). (Pubitemid 40755607)
5. Stevenson VL. Rehabilitation in practice: Spasticity management. Clin. Rehabil. 24, 293-304 (2010).
6. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 10, 589-595 (2004). (Pubitemid 39207235)
7. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 2, CD001332 (2004).
8. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult. Scler. 12, 646-651 (2006). (Pubitemid 46940639)
9. Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today 42, 495-501 (2006).
10. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: Results of a nationwide survey. Int. J. Clin. Pract. 59, 291-295 (2005). (Pubitemid 40352745)
11. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther. Clin. Risk Manag. 4, 245-249 (2008).
12. Pertwee RG. Cannabinoid pharmacology: The first 66 years. Br. J. Pharmacol. 147, S163-S171 (2006). (Pubitemid 43077274)
13. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 18, 129-140 (2007). (Pubitemid 46412082)
14. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br. J. Pharmacol. 150, 19-25 (2007).
15. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17(1), 21-29 (2003). (Pubitemid 36230977)
16. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler. 10(4), 425-433 (2004). (Pubitemid 39117340)
17. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329(7460), 253 (2004).
18. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38(1), 44-48 (1997). (Pubitemid 27283078)
19. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A; on behalf of the UK MS Research Group. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 362, 1517-1526 (2003). (Pubitemid 37410189)
20. Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10, 434-441 (2004). (Pubitemid 39117341)
21. Aldington S, Harwood M, Cox B; on behalf of the Cannabis and Respiratory Disease Research Group. Cannabis use and risk of lung cancer: A case-control study. Eur. Resp. J. 31, 280-286 (2008).
22. Martinez-Rodriguez JE, Munteis E, Carreno M et al. Cannabis use in Spanish patients with multiple sclerosis: Fulfilment of patients' expectations? J. Neurol. Sci. 273, 103-107 (2008).
23. Farrar JT, Troxel A, Stott CG, Duncombe P. The validity, reliability and clinical importance of changes in spasticity severity measured on a 0-10 Numerical Rating Scale. J. Neurol. 254(Suppl. 3), 21 (2007).
24. Fleuren JF, Voerman GE, Erren-Wolters CV et al. Stop using the Ashworth Scale for the assessment of spasticity. J. Neurol. Neurosurg. Psychiatry 81(1), 46-52 (2010).
25. Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profiles of inhaled delta-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: Implications for possible symptomatic treatment in multiple sclerosis. Eur. J. Neurol. 15(Suppl. 3), 365 (2008).
26. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 12, 639-645 (2006). (Pubitemid 46940638)
27. Collin C, Davies P, Mutiboko IK, Ratcliffe S; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14, 290-296 (2007). (Pubitemid 46384865)
28. Collin C, Serpell M, Potts R. Results of an open-label extension trial of Sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity. Mult. Scler. 13, S129 (2007).
29. Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32, 451-459 (2010).
30. Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. doi: 10.1111/j.1468-1331.2010.03328.x (2011) (Epub ahead of print).
31. Notcutt W, Davies P, Langford R, Ratcliffe S. Results of a randomised withdrawal study of subjects with spasticity due to multiple sclerosis who were receiving long term Sativex®. Mult. Scler. 15, S258 (2009).
32. Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler. 16, 1349-1359 (2010).
33. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65, 812-819 (2005). (Pubitemid 41362120)
34. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta-9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin. Ther. 29, 2068-2079 (2007). (Pubitemid 350218115)
35. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler. 16, 707-714 (2010).
36. Montalbán X, Wright S. Trial period for new symptomatic treatments: Lessons learnt from a Sativex in MS spasticity clinical trial. Mult. Scler. 15, S272 (2009).
37. House H, Bateman C, Wade DT. Long-term Sativex (THC:CBD) use in multiple sclerosis: Benefits to daily life and functional activities. Mult. Scler. 13, S267 (2007).
38. Constantinescu CS, Sarantis N. Long-term open-label treatment with Sativex® in patients with multiple sclerosis. Mult. Scler. 12, S111 (2006).
39. Sativex oromucosal spray: Summary of product characteristics. Almirall, Spain (2010).
40. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend. 42, 201-207 (1996). (Pubitemid 26356554)
41. Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis? Can. J. Psych. 51, 556-565 (2006). (Pubitemid 44338229)
42. Dannon PN, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. Comorbid cannabis use and panic disorder: Short term and long term follow-up study. Hum. Psychopharmacol. 19, 97-101 (2004). (Pubitemid 38332056)
43. Iversen L. Long-term effects of exposure to cannabis. Curr. Opin. Pharmacol. 5, 69-72 (2005). (Pubitemid 40124537)
44. Aragona M, Onesti E, Tomassini V et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: A double-blind, placebo controlled, crossover study. Clin. Neuropharmacol. 32, 41-47 (2009).
45. Schoedel K, Chen N, Guy GW et al. Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users. Eur. Neuropsychopharmacol. 20 (Suppl. 3), S587 (2010) 46 Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: A multimodal approach. Clin. Ther. 28, 445-460 (2006).